The Financial Express2h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
Harnessing AI and data science to discover life-changing medicines at AstraZeneca
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
ジャパンタイムズ1d
AstraZeneca and Daiichi Sankyo win U.S. approval for breast cancer drug
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...
FiercePharma1d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
News Medical on MSN2d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca rises Thursday, outperforms market
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
GlobalData on MSN3d
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead
CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January.
Guggenheim lifts AstraZeneca stock target, buy rating on prospects
Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...